blog/
20 pages · Updated May 1, 2026
Pages
- Prolia (denosumab) Prior Authorization Guide: Navigating Access Across Major U.S. Payers
- What’s Driving Billions in Part B & D Spending? 10 Most Expensive Drugs in Medicare
- Lucentis (Ranibizumab) Prior Authorization Guide: Navigating Access Across Major U.S. Payers
- Specialty Drug Billing Dilemma: Is Medical or Pharmacy the Winning Move?
- Buy‑and‑Bill Denial Prevention: Top 10 Root Causes and How to Fix Them
- Audit Readiness for Infusion & SP: Documentation That Survives Payer Reviews
- Navigating Eylea (Aflibercept) Prior Authorization Policies Across Major U.S. Payers
- Remicade (infliximab) Prior-Authorization Guide: Policies, Codes & Access Insights
- Medicare Part B Drug-Pricing Reforms Coming in 2026—What Providers Should Do Now
- The Dirty Seven: 7 Prior-Authorization Denial Codes Costing Infusion Centers the Most
- Medicare Part B Margins Decreasing Under New Bill
- How the Big Beautiful Bill Impacts Infusion Clinic Margins
- Keytruda (Pembrolizumab): Prior Authorization Guidelines and Utilization Overview Across Major U.S. Payers
- Units, Modifiers, and MUE Pitfalls: Coding Essentials for Infusion Services
- Biosimilars in 2025: Adoption Strategies That Save Infusion Centers 20 % on Drug Spend
- Prepare for 4% Medicare Cuts: 5 Steps Clinics Must Take
- NDC‑to‑HCPCS Crosswalk Guide: Avoid J‑Code Errors on Infusion Claims
- Vial Optimization & JW Modifier: Cut Drug Waste and Denials
- Navigating 340B, Site-Neutral & Prior-Auth Rules After the 2025 Executive Order
- Articles & insights to keep you updated on our latest developments